StockTipsArenaBeta

BUY Tatva Chintan Pharma Chem Limited — Ajit Mishra, Religare

BUYTatva Chintan Pharma Chem Limited
Tatva Chintan Pharma Chem share price target & all analyst calls

byAjit Mishra, ReligareHorizon: NA (inferred Swing (≤2wk))13 Jul 2026via ET Now

Entry₹1,389.6Inferred
Target₹1,700
Total upside +22.34% (call closed)
Stop loss₹1,300-6.45% risk
Exit₹1,70020 Jul 2026, 9:40 am
Target hit+22.34%0.00%upside left
Follow Ajit Mishra for new calls(22% target hit, 115 closed calls)Get alertsWatch TATVA for new buy/sell callsGet alertsSee 142 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 20 Jul 2026
2 supporting2 neutral0 opposing
Supports the BUY call (2)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·20 Jul · today

Tatva Chintan Q1 profit more than doubles as revenue jumps 43%; approves ₹200 crore capacity expansion

NewsCnbc-Tv18·17 Jul · 2d ago

(opens in new tab)
Neutral / worth noting (2)

The Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, and the limited review report. They also approved the re-appointment of Mr. Chintan Nitinkumar Shah

BSE · Board Meeting·17 Jul · 2d ago

(opens in new tab)

Tatva Chintan Pharma Chem Limited has announced its unaudited financial results for the quarter ended June 30, 2026. The board also approved the re-appointment of its Managing Director and two Whole-t

NSE · Outcome of Board Meeting·17 Jul · 2d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Tatva Chintan Pharma Chem

All analyst calls on Tatva Chintan Pharma Chem

More from Ajit Mishra, Religare

Every call and its outcome